Advisory Board

Meet the Board of Advisers

Thrombosisadviser.com provides up-to-date information for physicians and patients on thromboembolic diseases.

It was developed in collaboration with a board of advisers, comprised of recognised experts in the field of thrombosis.

The Board of Advisers is dedicated to fostering awareness and understanding about new approaches in prevention, diagnosis, and treatment of thromboembolic diseases. It will provide ongoing support for the site.

Professor Sylvia Haas, MD

Sylvia Haas is a professor of medicine and had been director of the Haemostasis and Thrombosis Research Group at the Institute for Experimental Oncology and Therapy Research, Technical University of Munich, Germany.

Professor Haas’ scientific focus is the development of new antithrombotic therapies, laboratory monitoring of anticoagulants, biomarkers, and tumour-associated thrombosis. Professor Haas is involved in several clinical trials — in particular, trials involving the prevention and treatment of arterial and venous thromboembolism.

Professor Sylvia Haas, MD

She is a member of several international professional societies, including the International Society on Thrombosis and Haemostasis and the International Society of Angiology, and she is a fellow of the Southern African Society of Thrombosis and Haemostasis, the European Society for Surgical Research, and the German Societies of Surgery, Angiology, and Thrombosis and Haemostasis Research. She is also a member of the editorial board for several peer-reviewed journals, including Current Hematology Reports, International Journal of Angiology, and Clinical and Applied Thrombosis/Hemostasis.

Professor Haas holds a medical degree from the University of Freiburg and began her training in paediatric haematology and oncology at the University of Munich. She continued her training in internal medicine at the Medical School, Technical University Munich and received full professorship after having established the Haemostasis and Thrombosis Research Group at the Institute for Experimental Surgery, which is now called the Institute for Experimental Oncology and Therapy Research.

Professor Gregory YH Lip, MD

Gregory YH Lip is a professor of cardiovascular medicine at the University of Birmingham, UK, and a consultant cardiologist and director of the Haemostasis Thrombosis and Vascular Biology Unit in the University Department of Medicine at City Hospital, Birmingham. Professor Lip was clinical adviser to the guideline development group which wrote the UK national NICE guidelines on the management of atrial fibrillation. He is on the panel that produced the American College of Chest Physicians Consensus Guidelines on Antithrombotic Therapy for Atrial Fibrillation, which are established international guidelines on thrombosis and thromboprophylaxis.

Professor Lip’s responsibilities include cardiovascular medicine (invasive and noninvasive cardiology), teaching, and cardiovascular research in atrial fibrillation, hypertension, heart failure, thrombosis and antithrombotic therapy, and ethnic differences in vascular disease. In addition, Professor Lip leads a large laboratory-based group that researches thrombosis and vascular biology in cardiovascular disease and stroke. His published work and lectures focus on the clinical epidemiology of atrial fibrillation, as well as on the pathophysiology of thrombosis in cardiovascular disease.

Professor Gregory YH Lip, MD

Professor Lip is grant coapplicant for the BAFTA (Birmingham Atrial Fibrillation Treatment in the Aged) clinical trial, which compares Aspirin and warfarin in elderly patients (aged >75) with atrial fibrillation in the primary care setting. He has also been involved in local epidemiological surveys of thromboprophylaxis for atrial fibrillation and the formulation of regional and national antithrombotic therapy guidelines for atrial fibrillation.

Professor Alexander GG Turpie, MD

Alexander GG Turpie is a professor of medicine at McMaster University and is an internist on the staff of Hamilton Health Sciences, Hamilton, Ontario, Canada.

Professor Turpie’s research interests include new antithrombotic drugs for the management of venous and arterial thrombosis and anticoagulant therapy in patients with prosthetic heart valves. He has served on numerous professional and university-related committees and is a frequent lecturer at professional meetings worldwide.

Professor Alexander GG Turpie, MD

He is the author of more than 700 published articles, abstracts, book chapters, and books, and a reviewer for many journals, including Annals of Internal Medicine, Circulation, The Lancet, and The New England Journal of Medicine. He also serves on the editorial boards of Vascular Medicine Review and HeartDrug.

Professor Turpie holds a medical degree from the University of Glasgow, Scotland. After completing residencies at the Royal Infirmary and Stobhill General Hospital, Glasgow, where he was also a clinical research fellow, he served as a clinic lecturer for the University of East Africa Medical School in Nairobi, Kenya. After returning to the University of Glasgow for additional training in haemostasis and thrombosis, he was appointed an MRC fellow at McMaster University, Hamilton, Canada, where he was also appointed to the full-time faculty in the Department of Medicine.

Professor Ajay K Kakkar, MBBS (Hons), BSc, PhD, FRCS

Ajay Kakkar is a professor of Surgical Sciences at Barts and the London School of Medicine and Dentistry, Queen Mary College, University of London. He is also a consultant surgeon at Barts and the Royal London Hospital and Director of the Thrombosis Research Institute, London, UK.

Professor Kakkar is actively involved with several professional and academic committees and is frequently invited to lecture at both national and international meetings. Professor Kakkar is the author of 100 papers — including original research, case studies, and reviews — in numerous journals, including BMJ, Cancer Research, The Lancet, and The New England Journal of Medicine.

Professor Ajay K Kakkar, MBBS (Hons), BSc, PhD, FRCS

Within his involvement in numerous international studies and registries investigating the prevention and management of venous thromboembolic disease and cancer-associated thrombosis, Professor Kakkar’s research interests include the role of antithrombotic therapy in prolonging survival in cancer and the role of coagulation serine proteases in tumour biology.

Professor Kakkar received his medical training at King’s College Hospital Medical School, London, UK.

Print page

Haemostasis: The prevention of blood loss, either by the physiological properties of vasoconstriction and coagulation or by surgical means.
Venous thromboembolism: A condition in which a blood clot (thrombus) forms in a vein, which in some cases then breaks free and enters the circulation as an embolus, finally lodging in and completely obstructing a blood vessel, e.g., in lungs causing a PE. The term encompasses both DVT and PE.
American College of Chest Physicians: Multidisciplinary international medical society based in Northbrook, Illinois, USA, that focuses on the treatment and prevention of all diseases of the chest. It has over 16,000 active members with physicians representing all chest medicine disciplines. Publishes the journal Chest.
Thromboprophylaxis: The use of medication or medical devices to prevent the formation of blood clots.
Hypertension: Persistently high arterial blood pressure. Hypertension may have no known cause (essential or idiopathic hypertension) or be associated with other primary diseases (secondary hypertension). This condition is considered a risk factor for the development of heart disease, peripheral vascular disease, stroke, and kidney disease.
Aspirin: The brand name of acetylsalicylic acid (ASA), an antithrombotic medication that prevents thrombosis by inhibiting the activity of platelets – a component of blood that helps to prevent blood loss.
Warfarin: A vitamin K antagonist. Most commonly used oral anticoagulant in chronic prevention or treatment of VTE.